Investigating the effect of the start time of dopamine agonist in antagonist cycles in reducing the rate of ovarian hyperstimulation syndrome
Not Applicable
- Conditions
- infertility.Female infertility associated with female factorsN97.4
- Registration Number
- IRCT20240514061800N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 124
Inclusion Criteria
Patients in the age range of 15 to 40, having at least one year of infertility history, patients with polycystic ovary syndrome using the Rotterdam criteria approved by the Rotterdam Joint Group in 2004. These criteria include having 17 or more follicles with a diameter of 10 mm or more on the trigger day, a peak estradiol level above 3,500 pg/ml, use of a GnRH antagonist protocol, use of a GnRH agonist, and cycles in which all embryos were cryopreserved. .
Exclusion Criteria
Having a history of sensitivity to cabergoline and other dopamine agonists, having heart, kidney, and liver disease, low response to ovarian stimulation and thus not being at risk of developing ovarian hyperstimulation syndrome, history of hyperprolactinemia.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reducing the rate of ovarian hyperstimulation syndrome. Timepoint: After the intervention. Method of measurement: Transvaginal ultrasound and estradiol level measurement.
- Secondary Outcome Measures
Name Time Method